Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Gross Profit (2016 - 2025)

Adma Biologics' Gross Profit history spans 13 years, with the latest figure at $88.8 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 40.24% year-over-year to $88.8 million; the TTM value through Dec 2025 reached $292.8 million, up 33.35%, while the annual FY2025 figure was $292.8 million, 33.35% up from the prior year.
  • Gross Profit reached $88.8 million in Q4 2025 per ADMA's latest filing, up from $75.6 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $88.8 million in Q4 2025 to a low of -$1.7 million in Q1 2021.
  • Average Gross Profit over 5 years is $31.9 million, with a median of $20.7 million recorded in 2023.
  • Peak YoY movement for Gross Profit: plummeted 117.75% in 2021, then skyrocketed 2406.02% in 2022.
  • A 5-year view of Gross Profit shows it stood at $3.5 million in 2021, then soared by 303.76% to $14.2 million in 2022, then skyrocketed by 119.27% to $31.1 million in 2023, then skyrocketed by 103.73% to $63.3 million in 2024, then surged by 40.24% to $88.8 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Gross Profit are $88.8 million (Q4 2025), $75.6 million (Q3 2025), and $67.2 million (Q2 2025).